FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Shader

Research Profile

Anatomy

Microsomes, Liver

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Richard I Shader
On top of atopy.
Richard I Shader
Health care reform.
Richard I Shader
The liver: a vulnerable helper.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Shader (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Richard I Shader
On top of atopy.
Clinical therapeutics 2013;35(5):541.
2013: Richard I Shader
Health care reform.
Clinical therapeutics 2013;35(4):351.
2013: Richard I Shader
The liver: a vulnerable helper.
Clinical therapeutics 2013;35(3):199-200.
2013: Richard I Shader
Influenza vaccines-thoughts and current status.
Clinical therapeutics 2013;35(2):101-2.
2013: Richard I Shader
A new year, a new look.
Clinical therapeutics 2013;35(1):1.
2012: Richard I Shader
Too good to be true? Aspirin and schizophrenia.
Journal of clinical psychopharmacology 2012;32(5):583-4.
2012: Erin N Umberg; L K George Hsu; Richard I Shader; David J Greenblatt
From disordered eating to addiction: the "food drug" in bulimia nervosa.
Journal of clinical psychopharmacology 2012;32(3):376-89.
2011: Donald F Klein; Ira D Glick; Richard I Shader
Central nervous system drug development, basic, and clinical research: thinking outside the box.
Journal of clinical psychopharmacology 2011;31(5):553-4.
2011: David J Greenblatt; Jerold S Harmatz; Richard I Shader
Psychotropic drug prescribing in the United States: extent, costs, and expenditures.
Journal of clinical psychopharmacology 2011;31(1):1-3.
2010: Richard I Shader
Good news and disappointing news: a new era in health care delivery.
Journal of clinical psychopharmacology 2010;30(3):223-4.
2010: Richard I Shader
Water safety, medication disposal, and more: an update.
Journal of clinical psychopharmacology 2010;30(1):1-2.
2009: Richard I Shader
The cart before the horse? Health insurance reform before health care reform.
Journal of clinical psychopharmacology 2009;29(5):413-4.
2009: Richard I Shader
Antidepressants as hydrobromide salts: are they a cause for concern?
Journal of clinical psychopharmacology 2009;29(4):317-8.
2008: Richard I Shader
Some personal reflections on health care reform.
Journal of clinical psychopharmacology 2008;28(6):599-600.
2008: Richard I Shader
Water, water everywhere: but is it safe to drink? Return to a muddy topic.
Journal of clinical psychopharmacology 2008;28(3):261-3.
2007: Richard I Shader
Dose dumping and the dumping of doses.
Journal of clinical psychopharmacology 2007;27(4):327-8.
2006: Jeanne M Fahey; Gary A Pritchard; Jyoti M Reddi; John Pratt; Jeffrey M Grassi; Richard I Shader; David J Greenblatt
The effect of chronic lorazepam administration in aging mice.
Brain research 2006;1118(1):13-24.
2006: Richard I Shader
Kynurenine--an old pathway retraced.
Journal of clinical psychopharmacology 2006;26(4):351-2.
2006: Richard I Shader; Jessica R Oesterheld
Facts and public policy: should I keep my child on ADHD drugs?
Journal of clinical psychopharmacology 2006;26(3):223-4.
2005: David J Greenblatt; Lu Gan; Jerold S Harmatz; Richard I Shader
Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test.
British journal of clinical pharmacology 2005;60(3):244-8.
2005: Richard I Shader
Demoralization revisited.
Journal of clinical psychopharmacology 2005;25(4):291-2.
2005: Benedetto Vitiello; Richard I Shader; Corette B Parker; Louise Ritz; William Harlan; David J Greenblatt; Kishore M Gadde; K Ranga Rama Krishnan; Jonathan R T Davidson
Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial.
Journal of clinical psychopharmacology 2005;25(3):243-9.
2005: Ira D Glick; Sidney Zisook; Richard I Shader
The challenge of teaching psychopharmacology and improving clinical practice.
Journal of clinical psychopharmacology 2005;25(3):203-5.
2004: David J Greenblatt; Jerold S Harmatz; Lisa L Von Moltke; C Eugene Wright; Richard I Shader
Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.
Clinical pharmacology and therapeutics 2004;76(5):467-79.
2004: David J Greenblatt; Bruce L Ehrenberg; Kerry E Culm; Joseph M Scavone; Kathleen E Corbett; Hylar L Friedman; Jerold S Harmatz; Richard I Shader
Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions.
Journal of clinical pharmacology 2004;44(6):605-11.
2004: David J Greenblatt; Richard I Shader
In memoriam: Louis Lasagna, MD 1923-2003.
Journal of clinical psychopharmacology 2004;24(3):243-4.
2004: Dennis Ross-Degnan; Linda Jean Simoni-Wastila; Jeffrey Brown; Xiaoming Gao; Connie Mah; Leon E Cosler; Thomas Fanning; Peter Gallagher; Carl Salzman; Richard I Shader; Thomas S Inui; Stephen B Soumerai
A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population.
International journal of psychiatry in medicine 2004;34(2):103-23.
2003: Richard I Shader
Drug-attributed hepatic failure: causality, risk assessment, consent, and confusion.
Journal of clinical psychopharmacology 2003;23(6):533-4.
2003: Jill S Warrington; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader; David J Greenblatt
The effect of age on sildenafil biotransformation in rat and mouse liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(11):1306-9.
2003: Joel O Olubodun; Hermann R Ochs; Lisa L Von Moltke; Ronenn Roubenoff; Leah M Hesse; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.
British journal of clinical pharmacology 2003;56(3):297-304.
2003: Richard I Shader
Antagonists, inverse agonists, and protagonists.
Journal of clinical psychopharmacology 2003;23(4):321-2.
2003: Richard I Shader
Foods, genetics, and drug interactions.
Journal of clinical psychopharmacology 2003;23(3):221-2.
2003: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Steven M Fogelman; Gengsheng Chen; Jennifer A Graf; Polyxane Mertzanis; Susan Byron; Kerry E Culm; Brian W Granda; Johanna Daily; Richard I Shader
Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.
Journal of clinical pharmacology 2003;43(4):414-22.
2003: Richard I Shader; David J Greenblatt
The safety of over-the-counter drugs: some reflections and unanswered questions.
Journal of clinical psychopharmacology 2003;23(2):111-2.
2002: Joel O Olubodun; Hermann R Ochs; Volker Trüten; Arno Klein; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use.
Journal of clinical pharmacology 2002;42(10):1142-6.
2002: Jill S Warrington; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):655-7.
2002: Richard I Shader
Discontinue after last dose--an editorial and information about prescription writing.
Journal of clinical psychopharmacology 2002;22(3):235.
2001: Michael D Perloff; Lisa L Von Moltke; Elke Störmer; Richard I Shader; David J Greenblatt
Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.
British journal of pharmacology 2001;134(8):1601-8.
2001: Karthik Venkatakrishnan; J Schmider; Jerold S Harmatz; Bruce L Ehrenberg; Lisa L Von Moltke; Jennifer A Graf; Polyxane Mertzanis; Kathleen E Corbett; M C Rodriguez; Richard I Shader; David J Greenblatt
Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies.
Journal of clinical pharmacology 2001;41(10):1043-54.
2001: Bruce Fogas; Jessica R Oesterheld; Richard I Shader
A retrospective study of children's perceptions of participation as clinical research subjects in a minimal risk study.
Journal of developmental and behavioral pediatrics : JDBP 2001;22(4):211-6.
2001: Lisa L Von Moltke; David J Greenblatt; Gina M Giancarlo; Brian W Granda; Jerold S Harmatz; Richard I Shader
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(8):1102-9.
2001: Jeanne M Fahey; Gary A Pritchard; Jeffrey M Grassi; John Pratt; Richard I Shader; David J Greenblatt
Pharmacodynamic and receptor binding changes during chronic lorazepam administration.
Pharmacology, biochemistry, and behavior 2001;69(1-2):1-8.
2001: Leah M Hesse; Karthik Venkatakrishnan; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(2):133-40.
2001: Leah M Hesse; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(2):100-2.
2001: Lisa L Von Moltke; David J Greenblatt; Brian W Granda; Gina M Giancarlo; Su X Duan; Johanna Daily; Jerold S Harmatz; Richard I Shader
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
Journal of clinical pharmacology 2001;41(1):85-91.
2000: Leah M Hesse; Karthik Venkatakrishnan; Michael H Court; Lisa L Von Moltke; Su X Duan; Richard I Shader; David J Greenblatt
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1176-83.
2000: Elke Störmer; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1168-75.
2000: David J Greenblatt; Lisa L Von Moltke; Bruce L Ehrenberg; Jerold S Harmatz; Kathleen E Corbett; D W Wallace; Richard I Shader
Kinetics and dynamics of lorazepam during and after continuous intravenous infusion.
Critical care medicine 2000;28(8):2750-7.
2000: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; AL Durol; Johanna Daily; Jennifer A Graf; Polyxane Mertzanis; J L Hoffman; Richard I Shader
Differential impairment of triazolam and zolpidem clearance by ritonavir.
Journal of acquired immune deficiency syndromes (1999) 2000;24(2):129-36.
2000: Gary B Kaplan; David J Greenblatt; Bruce L Ehrenberg; JE Goddard; Jerold S Harmatz; Richard I Shader
Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam.
Journal of clinical psychopharmacology 2000;20(3):338-46.
2000: David J Greenblatt; Jerold S Harmatz; Lisa L Von Moltke; C Eugene Wright; AL Durol; L M Harrel-Joseph; Richard I Shader
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
The Journal of pharmacology and experimental therapeutics 2000;293(2):435-43.
2000: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; AL Durol; Johanna Daily; Jennifer A Graf; Polyxane Mertzanis; J L Hoffman; Richard I Shader
Alprazolam-ritonavir interaction: implications for product labeling.
Clinical pharmacology and therapeutics 2000;67(4):335-41.
2000: Richard I Shader; Jessica R Oesterheld
Contraceptive effectiveness: cytochromes and induction.
Journal of clinical psychopharmacology 2000;20(2):119-21.
2000: A Zalma; Lisa L Von Moltke; Brian W Granda; Jerold S Harmatz; Richard I Shader; David J Greenblatt
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Biological psychiatry 2000;47(7):655-61.
2000: Jill S Warrington; Richard I Shader; Lisa L Von Moltke; David J Greenblatt
In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(4):392-7.
2000: J S Warrington; J W Poku; Lisa L Von Moltke; Richard I Shader; Jerold S Harmatz; David J Greenblatt
Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
The Journal of pharmacology and experimental therapeutics 2000;292(3):1024-31.
2000: Michael D Perloff; Lisa L Von Moltke; M H Court; Tsutomu Kotegawa; Richard I Shader; David J Greenblatt
Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
The Journal of pharmacology and experimental therapeutics 2000;292(2):618-28.
1999: Richard I Shader; Brian W Granda; Lisa L Von Moltke; Gina M Giancarlo; David J Greenblatt
Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast.
Biopharmaceutics & drug disposition 1999;20(8):385-8.
1999: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.
Journal of clinical psychopharmacology 1999;19(5 Suppl 1):23S-35S.
1999: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Karthik Venkatakrishnan; Su X Duan; Steven M Fogelman; Jerold S Harmatz; Richard I Shader
Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.
Biological psychiatry 1999;46(6):839-49.
1999: Richard I Shader; Jerold S Harmatz; Jessica R Oesterheld; D X Parmelee; F R Sallee; David J Greenblatt
Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder.
Journal of clinical pharmacology 1999;39(8):775-85.
1999: Lisa L Von Moltke; David J Greenblatt; Brian W Granda; Jeffrey M Grassi; J Schmider; Jerold S Harmatz; Richard I Shader
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
Psychopharmacology 1999;145(1):113-22.
1999: Lisa L Von Moltke; David J Greenblatt; Brian W Granda; Su X Duan; Jeffrey M Grassi; Karthik Venkatakrishnan; Jerold S Harmatz; Richard I Shader
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.
British journal of clinical pharmacology 1999;48(1):89-97.
1999: J Schmider; Lisa L Von Moltke; Richard I Shader; Jerold S Harmatz; David J Greenblatt
Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.
Drug metabolism reviews 1999;31(2):545-60.
1999: Steven M Fogelman; J Schmider; Karthik Venkatakrishnan; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader; David J Greenblatt
O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(5):480-90.
1999: Jeanne M Fahey; Gary A Pritchard; Jeffrey M Grassi; John Pratt; Richard I Shader; David J Greenblatt
In situ hybridization histochemistry as a method to assess GABA(A) receptor subunit mRNA expression following chronic alprazolam administration.
Journal of psychopharmacology (Oxford, England) 1999;13(3):211-8.
1999: Jeanne M Fahey; Gary A Pritchard; John Pratt; Richard I Shader; David J Greenblatt
Lorazepam attenuates the behavioral effects of dizocilpine.
Pharmacology, biochemistry, and behavior 1999;62(1):103-10.
1998: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Steven M Fogelman; Jerold S Harmatz; S J Kramer; L F Fabre; Richard I Shader
Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects.
Psychopharmacology 1998;140(3):293-9.
1998: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Polyxane Mertzanis; Jennifer A Graf; AL Durol; M Counihan; B Roth-Schechter; Richard I Shader
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.
Clinical pharmacology and therapeutics 1998;64(6):661-71.
1998: David J Greenblatt; Jerold S Harmatz; Lisa L Von Moltke; Bruce L Ehrenberg; L Harrel; Kathleen E Corbett; M Counihan; Jennifer A Graf; Mona Darwish; Polyxane Mertzanis; PT Martin; WH Cevallos; Richard I Shader
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
Clinical pharmacology and therapeutics 1998;64(5):553-61.
1998: Lisa L Von Moltke; David J Greenblatt; Su X Duan; Johanna Daily; Jerold S Harmatz; Richard I Shader
Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
Journal of pharmaceutical sciences 1998;87(10):1184-9.
1998: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Karthik Venkatakrishnan; J Schmider; Jerold S Harmatz; Richard I Shader
Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
The Journal of pharmacy and pharmacology 1998;50(9):997-1004.
1998: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; M Counihan; Jennifer A Graf; AL Durol; Polyxane Mertzanis; Su X Duan; C Eugene Wright; Richard I Shader
Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Clinical pharmacology and therapeutics 1998;64(3):278-85.
1998: David J Greenblatt; C Eugene Wright; Lisa L Von Moltke; Jerold S Harmatz; Bruce L Ehrenberg; L M Harrel; Kathleen E Corbett; M Counihan; S Tobias; Richard I Shader
Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Clinical pharmacology and therapeutics 1998;64(3):237-47.
1998: Lisa L Von Moltke; David J Greenblatt; D A Ciraulo; Jeffrey M Grassi; Brian W Granda; Su X Duan; Jerold S Harmatz; Richard I Shader
Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine.
Journal of clinical psychopharmacology 1998;18(4):338-41.
1998: Richard I Shader; Steven M Fogelman; David J Greenblatt
Epiphenomenal, causal, or correlational--more on the mechanism(s) of action of antidepressants.
Journal of clinical psychopharmacology 1998;18(4):265-7.
1998: Joseph M Scavone; David J Greenblatt; Jerold S Harmatz; N Engelhardt; Richard I Shader
Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers.
Journal of clinical pharmacology 1998;38(7):603-9.
1998: Karthik Venkatakrishnan; David J Greenblatt; Lisa L Von Moltke; Richard I Shader
Alprazolam is another substrate for human cytochrome P450-3A isoforms.
Journal of clinical psychopharmacology 1998;18(3):256.
1998: Jessica R Oesterheld; Richard I Shader
Cytochromes: a primer for child and adolescent psychiatrists.
Journal of the American Academy of Child and Adolescent Psychiatry 1998;37(4):447-50.
1998: Jeanne M Fahey; Gary A Pritchard; L L Moltke; John Pratt; Jeffrey M Grassi; Richard I Shader; David J Greenblatt
Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice.
The Journal of pharmacology and experimental therapeutics 1998;285(1):271-6.
1998: Karthik Venkatakrishnan; Lisa L Von Moltke; Su X Duan; Joseph C Fleishaker; Richard I Shader; David J Greenblatt
Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
The Journal of pharmacy and pharmacology 1998;50(3):265-74.
1998: Karthik Venkatakrishnan; David J Greenblatt; Lisa L Von Moltke; J Schmider; Jerold S Harmatz; Richard I Shader
Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
Journal of clinical pharmacology 1998;38(2):112-21.
1998: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Su X Duan; Steven M Fogelman; Johanna Daily; Jerold S Harmatz; Richard I Shader
Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.
Journal of clinical pharmacology 1998;38(2):106-11.
1998: Lisa L Von Moltke; David J Greenblatt; J Schmider; C Eugene Wright; Jerold S Harmatz; Richard I Shader
In vitro approaches to predicting drug interactions in vivo.
Biochemical pharmacology 1998;55(2):113-22.
1998: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
Drug interactions with newer antidepressants: role of human cytochromes P450.
The Journal of clinical psychiatry 1998;59 Suppl 15():19-27.
1998: Gary B Kaplan; David J Greenblatt; Bruce L Ehrenberg; JE Goddard; Jerold S Harmatz; Richard I Shader
Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects.
Journal of clinical pharmacology 1998;38(1):14-21.
1997: J Schmider; David J Greenblatt; Lisa L Von Moltke; D Karsov; Richard I Shader
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
British journal of clinical pharmacology 1997;44(5):495-8.
1997: Gary B Kaplan; David J Greenblatt; Bruce L Ehrenberg; JE Goddard; Monette M Cotreau; Jerold S Harmatz; Richard I Shader
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans.
Journal of clinical pharmacology 1997;37(8):693-703.
1997: Lisa L Von Moltke; David J Greenblatt; Su X Duan; J Schmider; C Eugene Wright; Jerold S Harmatz; Richard I Shader
Human cytochromes mediating N-demethylation of fluoxetine in vitro.
Psychopharmacology 1997;132(4):402-7.
1997: Joseph M Scavone; David J Greenblatt; Darrell R. Abernethy; B G Luna; Jerold S Harmatz; Richard I Shader
Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics.
Journal of clinical pharmacology 1997;37(5):437-41.
1997: Richard I Shader; Steven M Fogelman; David J Greenblatt
Newer antidepressants: further reflections.
Journal of clinical psychopharmacology 1997;17(2):75-7.
1997: J Schmider; David J Greenblatt; Steven M Fogelman; Lisa L Von Moltke; Richard I Shader
Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Biopharmaceutics & drug disposition 1997;18(3):227-40.
1997: Michael H Court; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species.
Biopharmaceutics & drug disposition 1997;18(3):213-26.
1997: K P Charpentier; Lisa L Von Moltke; J W Poku; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction.
Biopharmaceutics & drug disposition 1997;18(2):139-49.
1997: J Schmider; David J Greenblatt; Lisa L Von Moltke; D Karsov; R Vena; H L Friedman; Richard I Shader
Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors.
Journal of clinical pharmacology 1997;37(3):193-200.
1997: Lisa L Von Moltke; Su X Duan; David J Greenblatt; Steven M Fogelman; J Schmider; Jerold S Harmatz; Richard I Shader
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms.
Biological psychiatry 1997;41(3):377-80.
1997: Richard I Shader; Steven M Fogelman; David J Greenblatt
Newer antidepressants: hypotheses and evidence.
Journal of clinical psychopharmacology 1997;17(1):1-3.
1996: Lisa L Von Moltke; David J Greenblatt; Su X Duan; J Schmider; L Kudchadker; Steven M Fogelman; Jerold S Harmatz; Richard I Shader
Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.
Psychopharmacology 1996;128(4):398-407.
1996: David J Greenblatt; Lisa L Von Moltke; J Schmider; Jerold S Harmatz; Richard I Shader
Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.
Journal of clinical pharmacology 1996;36(9):792-8.
1996: Lisa L Von Moltke; David J Greenblatt; J Schmider; Su X Duan; C Eugene Wright; Jerold S Harmatz; Richard I Shader
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
Journal of clinical pharmacology 1996;36(9):783-91.
1996: Domenic A Ciraulo; O Sarid-Segal; C Knapp; Ann Marie Ciraulo; David J Greenblatt; Richard I Shader
Liability to alprazolam abuse in daughters of alcoholics.
The American journal of psychiatry 1996;153(7):956-8.
1996: J Schmider; David J Greenblatt; Jerold S Harmatz; Richard I Shader
Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation.
British journal of clinical pharmacology 1996;41(6):593-604.
1996: J Schmider; David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation.
British journal of clinical pharmacology 1996;41(4):339-43.
1996: Lisa L Von Moltke; David J Greenblatt; Su X Duan; Jerold S Harmatz; C Eugene Wright; Richard I Shader
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
Journal of clinical psychopharmacology 1996;16(2):104-12.
1996: J Schmider; David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Su X Duan; D Karsov; Richard I Shader
Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies.
Pharmacology 1996;52(2):125-34.
1996: Lisa L Von Moltke; David J Greenblatt; Jerold S Harmatz; Su X Duan; L M Harrel; M M Cotreau-Bibbo; Gary A Pritchard; C Eugene Wright; Richard I Shader
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
The Journal of pharmacology and experimental therapeutics 1996;276(2):370-9.
1995: J Schmider; David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.
The Journal of pharmacology and experimental therapeutics 1995;275(2):592-7.
1995: Lisa L Von Moltke; David J Greenblatt; Michael H Court; Su X Duan; Jerold S Harmatz; Richard I Shader
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
Journal of clinical psychopharmacology 1995;15(2):125-31.
1995: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; L M Harrel; S Tobias; Richard I Shader; C Eugene Wright
Interaction of triazolam and ketoconazole.
Lancet 1995;345(8943):191.
1995: Lisa L Von Moltke; David J Greenblatt; J Schmider; Jerold S Harmatz; Richard I Shader
Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.
Clinical pharmacokinetics 1995;29 Suppl 1():33-43; discussion 43-4.
1994: Lisa L Von Moltke; David J Greenblatt; Su X Duan; Jerold S Harmatz; Richard I Shader
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
Journal of clinical pharmacology 1994;34(12):1222-7.
1994: David J Greenblatt; Jerold S Harmatz; T A Gouthro; J Locke; Richard I Shader
Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies.
Clinical pharmacology and therapeutics 1994;56(1):100-11.
1994: Lisa L Von Moltke; David J Greenblatt; M M Cotreau-Bibbo; Jerold S Harmatz; Richard I Shader
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.
British journal of clinical pharmacology 1994;38(1):23-31.
1994: Lisa L Von Moltke; David J Greenblatt; M M Cotreau-Bibbo; Su X Duan; Jerold S Harmatz; Richard I Shader
Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
The Journal of pharmacology and experimental therapeutics 1994;268(3):1278-83.
1993: Lisa L Von Moltke; David J Greenblatt; Jerold S Harmatz; Richard I Shader
Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes.
Pharmacology 1993;47(4):268-76.
1993: David J Greenblatt; Jerold S Harmatz; Richard I Shader
Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
Archives of general psychiatry 1993;50(9):715-22.
1993: Richard I Shader; David J Greenblatt
Use of benzodiazepines in anxiety disorders.
The New England journal of medicine 1993;328(19):1398-405.
1993: John J Byrnes; L G Miller; K Perkins; David J Greenblatt; Richard I Shader
Chronic benzodiazepine administration. XI. Concurrent administration of PK11195 attenuates lorazepam discontinuation effects.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1993;8(3):267-73.
1993: David J Greenblatt; J M Scavone; Jerold S Harmatz; N Engelhardt; Richard I Shader
Cognitive effects of beta-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo.
Clinical pharmacology and therapeutics 1993;53(5):577-84.
1993: Lisa L Von Moltke; David J Greenblatt; Richard I Shader
Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.
Clinical pharmacokinetics 1993;24(2):141-60.
1993: John J Byrnes; L G Miller; David J Greenblatt; Richard I Shader
Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam.
Psychopharmacology 1993;111(1):91-5.
1992: Gary B Kaplan; David J Greenblatt; M A Kent; M M Cotreau; G Arcelin; Richard I Shader
Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1992;6(3):145-53.
1992: F Lopez; L G Miller; David J Greenblatt; A Schatzki; M Lumpkin; Richard I Shader
Chronic low-dose alprazolam augments gamma-aminobutyric acid(A) receptor function.
Journal of clinical psychopharmacology 1992;12(2):119-23.
1992: L G Miller; W R Galpern; John J Byrnes; David J Greenblatt; Richard I Shader
Chronic benzodiazepine administration. X. Concurrent administration of the peripheral-type benzodiazepine ligand PK11195 attenuates chronic effects of lorazepam.
The Journal of pharmacology and experimental therapeutics 1992;261(1):285-9.
1992: J M Scavone; David J Greenblatt; J E Goddard; H Friedman; J S Harmatz; Richard I Shader
The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.
European journal of clinical pharmacology 1992;42(4):439-43.
1991: W R Galpern; L G Miller; David J Greenblatt; GK Szabo; TR Browne; Richard I Shader
Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine.
Biochemical pharmacology 1991;42 Suppl():S99-104.
1991: David J Greenblatt; Jerold S Harmatz; Richard I Shader
Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).
Clinical pharmacokinetics 1991;21(4):262-73.
1991: L G Miller; S Chesley; W R Galpern; David J Greenblatt; Richard I Shader
Prenatal benzodiazepine administration. II. Lorazepam exposure is associated with decreases in [35S]TBPS binding but not benzodiazepine binding.
Pharmacology, biochemistry, and behavior 1991;40(2):429-32.
1991: Richard I Shader; David J Greenblatt; MB Balter
Appropriate use and regulatory control of benzodiazepines.
Journal of clinical pharmacology 1991;31(9):781-4.
1991: David J Greenblatt; Jerold S Harmatz; Richard I Shader
Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I).
Clinical pharmacokinetics 1991;21(3):165-77.
1991: David J Greenblatt; Jerold S Harmatz; L Shapiro; N Engelhardt; T A Gouthro; Richard I Shader
Sensitivity to triazolam in the elderly.
The New England journal of medicine 1991;324(24):1691-8.
1991: L G Miller; M Lumpkin; W R Galpern; David J Greenblatt; Richard I Shader
Modification of gamma-aminobutyric acidA receptor binding and function by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vitro and in vivo: effects of aging.
Journal of neurochemistry 1991;56(4):1241-7.
1991: W R Galpern; M Lumpkin; David J Greenblatt; Richard I Shader; L G Miller
Chronic benzodiazepine administration. VII. Behavioral tolerance and withdrawal and receptor alterations associated with clonazepam administration.
Psychopharmacology 1991;104(2):225-30.
1991: J G Barnhill; L G Miller; David J Greenblatt; M L Thompson; Domenic A Ciraulo; Richard I Shader
Benzodiazepine receptor binding response to acute and chronic stress is increased in aging animals.
Pharmacology 1991;42(4):181-7.
1991: S Chesley; M Lumpkin; A Schatzki; W R Galpern; David J Greenblatt; Richard I Shader; L G Miller
Prenatal exposure to benzodiazepine--I. Prenatal exposure to lorazepam in mice alters open-field activity and GABAA receptor function.
Neuropharmacology 1991;30(1):53-8.
1990: David J Greenblatt; J I Javaid; A Locniskar; Jerold S Harmatz; Richard I Shader
Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity.
Journal of chromatography 1990;534():202-7.
1990: W R Galpern; L G Miller; David J Greenblatt; Richard I Shader
Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABAA-receptor function.
British journal of pharmacology 1990;101(4):839-42.
1990: S F Chesley; A D Schatzki; J DeUrrutia; David J Greenblatt; Richard I Shader; L G Miller
Cocaine augments peripheral benzodiazepine binding in humans.
The Journal of clinical psychiatry 1990;51(10):404-6.
1990: L G Miller; J Heller; M Lumpkin; C L Weill; David J Greenblatt; Richard I Shader
Augmentation of GABAA receptor function by chronic exposure to GABA-neutral and GABA-negative benzodiazepine ligands in cultured cortical neurons.
Biochemical pharmacology 1990;40(6):1337-44.
1990: Gary B Kaplan; N T Tai; David J Greenblatt; Richard I Shader
Caffeine-induced behavioural stimulation is dose- and concentration-dependent.
British journal of pharmacology 1990;100(3):435-40.
1990: L G Miller; W R Galpern; David J Greenblatt; M Lumpkin; Richard I Shader
Chronic benzodiazepine administration. VI. A partial agonist produces behavioral effects without tolerance or receptor alterations.
The Journal of pharmacology and experimental therapeutics 1990;254(1):33-8.
1990: J G Barnhill; David J Greenblatt; L G Miller; A Gaver; Jerold S Harmatz; Richard I Shader
Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals.
The Journal of pharmacology and experimental therapeutics 1990;253(3):1153-61.
1990: K A Lapierre; David J Greenblatt; J E Goddard; Jerold S Harmatz; Richard I Shader
The neuropsychiatric effects of aspartame in normal volunteers.
Journal of clinical pharmacology 1990;30(5):454-60.
1990: F Lopez; L G Miller; David J Greenblatt; S Chesley; A Schatzki; Richard I Shader
Chronic administration of benzodiazepines--V. Rapid onset of behavioral and neurochemical alterations after discontinuation of alprazolam.
Neuropharmacology 1990;29(3):237-41.
1990: Domenic A Ciraulo; E J Antal; R B Smith; D R Olson; D A Goldberg; E H Rand; R B Raskin; J P Phillips; Richard I Shader; David J Greenblatt
The relationship of alprazolam dose to steady-state plasma concentrations.
Journal of clinical psychopharmacology 1990;10(1):27-32.
1990: D H Baron; B F Sands; Domenic A Ciraulo; Richard I Shader
The diagnosis and treatment of panic disorder in alcoholics: three cases.
The American journal of drug and alcohol abuse 1990;16(3-4):287-95.
1990: Gary B Kaplan; N T Tai; David J Greenblatt; Richard I Shader
Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo.
Psychopharmacology 1990;101(4):539-44.
1990: L G Miller; David J Greenblatt; F Lopez; A Schatzki; J Heller; M Lumpkin; Richard I Shader
Chronic benzodiazepine administration: effects in vivo and in vitro.
Advances in biochemical psychopharmacology 1990;46():167-75.
1990: F Lopez; L G Miller; M L Thompson; A Schatzki; S Chesley; David J Greenblatt; Richard I Shader
Chronic morphine administration augments benzodiazepine binding and GABAA receptor function.
Psychopharmacology 1990;101(4):545-9.
1989: A Locniskar; David J Greenblatt; Jerold S Harmatz; Richard I Shader
Bioinequivalence of a generic brand of diazepam.
Biopharmaceutics & drug disposition 1989;10(6):597-605.
1989: David J Greenblatt; Jerold S Harmatz; H Friedman; A Locniskar; Richard I Shader
A large-sample study of diazepam pharmacokinetics.
Therapeutic drug monitoring 1989;11(6):652-7.
1989: Domenic A Ciraulo; J G Barnhill; Ann Marie Ciraulo; David J Greenblatt; Richard I Shader
Parental alcoholism as a risk factor in benzodiazepine abuse: a pilot study.
The American journal of psychiatry 1989;146(10):1333-5.
1989: David J Greenblatt; Richard I Shader; Jerold S Harmatz
Implications of altered drug disposition in the elderly: studies of benzodiazepines.
Journal of clinical pharmacology 1989;29(10):866-72.
1989: A Schatzki; F Lopez; David J Greenblatt; Richard I Shader; L G Miller
Lorazepam discontinuation promotes 'inverse agonist' effects of benzodiazepines.
British journal of pharmacology 1989;98(2):451-4.
1989: David J Greenblatt; B L Ehrenberg; J Gunderman; J M Scavone; N T Tai; Jerold S Harmatz; Richard I Shader
Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam.
The Journal of pharmacology and experimental therapeutics 1989;250(1):134-40.
1989: H Friedman; David J Greenblatt; J M Scavone; E S Burstein; H R Ochs; Jerold S Harmatz; Richard I Shader
Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women.
Clinical pharmacokinetics 1989;16(5):312-6.
1989: David J Greenblatt; Jerold S Harmatz; N Engelhardt; Richard I Shader
Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam.
Archives of general psychiatry 1989;46(4):326-32.
1989: Gary B Kaplan; David J Greenblatt; B W Leduc; M L Thompson; Richard I Shader
Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity.
The Journal of pharmacology and experimental therapeutics 1989;248(3):1078-83.
1989: David J Greenblatt; M K Divoll; Darrell R. Abernethy; H R Ochs; Jerold S Harmatz; Richard I Shader
Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition.
Pharmacology 1989;38(5):327-34.
1988: Domenic A Ciraulo; B F Sands; Richard I Shader
Critical review of liability for benzodiazepine abuse among alcoholics.
The American journal of psychiatry 1988;145(12):1501-6.
1988: Domenic A Ciraulo; J G Barnhill; David J Greenblatt; Richard I Shader; Ann Marie Ciraulo; M F Tarmey; M A Molloy; M E Foti
Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men.
The Journal of clinical psychiatry 1988;49(9):333-7.
1988: David J Greenblatt; Jerold S Harmatz; C Dorsey; Richard I Shader
Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo.
Clinical pharmacology and therapeutics 1988;44(3):326-34.
1988: David J Greenblatt; M K Divoll; M H Soong; H G Boxenbaum; Jerold S Harmatz; Richard I Shader
Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam.
Journal of clinical pharmacology 1988;28(9):853-9.
1988: H Friedman; David J Greenblatt; E S Burstein; J M Scavone; Jerold S Harmatz; Richard I Shader
Triazolam kinetics: interaction with cimetidine, propranolol, and the combination.
Journal of clinical pharmacology 1988;28(3):228-33.
1988: L G Miller; David J Greenblatt; J G Barnhill; Richard I Shader
Differential modulation of benzodiazepine receptor binding by ethanol in LS and SS mice.
Pharmacology, biochemistry, and behavior 1988;29(3):471-7.
1988: David J Greenblatt; M K Divoll; Jerold S Harmatz; Richard I Shader
Antipyrine absorption and disposition in the elderly.
Pharmacology 1988;36(2):125-33.
1987: J S Kennedy; H Friedman; J M Scavone; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Effect of blood collection tubes on antidepressant concentrations.
Journal of chromatography 1987;423():373-5.
1987: J S Kennedy; B W Leduc; J M Scavone; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods.
Journal of chromatography 1987;422():274-80.
1987: David J Greenblatt; L G Miller; Richard I Shader
Clonazepam pharmacokinetics, brain uptake, and receptor interactions.
The Journal of clinical psychiatry 1987;48 Suppl():4-11.
1987: H R Ochs; David J Greenblatt; H Friedman; E S Burstein; A Locniskar; Jerold S Harmatz; Richard I Shader
Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol.
Clinical pharmacology and therapeutics 1987;41(5):562-70.
1987: David J Greenblatt; Richard I Shader
Drug absorption rate: a critical component of bioequivalence assessment in psychopharmacology.
Journal of clinical pharmacology 1987;27(2):85-6.